Decipher Labs

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE643N01012
  • NSEID:
  • BSEID: 524752
INR
9.67
0.18 (1.9%)
BSENSE

Dec 04

BSE+NSE Vol: 7.06 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

7.06 k (-3.87%) Volume

Shareholding (Sep 2025)

FII

0.00%

Held by 0 FIIs

DII

0.00%

Held by 0 DIIs

Promoter

16.43%

Who are the top shareholders of the Decipher Labs?

06-Jun-2025

The top shareholders of Decipher Labs include Ajjarapu Janakiram with 16.43% and Seshu Srinivas Akula with 3.8%. Individual investors collectively own 80.75% of the shares, with no institutional or pledged promoter holdings reported.

The top shareholders of Decipher Labs include Ajjarapu Janakiram, who holds the largest stake at 16.43%. The highest public shareholder is Seshu Srinivas Akula, with a holding of 3.8%. Additionally, individual investors collectively own a significant portion of the company, accounting for 80.75% of the shares. There are no institutional holdings or pledged promoter holdings reported.

Read More

Has Decipher Labs declared dividend?

06-Jun-2025

No Dividend History Available

Who are the peers of the Decipher Labs?

03-Jun-2025

Decipher Labs' peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, and others. While Sun Pharma and Cipla show excellent management and growth, Decipher Labs has below-average growth and capital structure, with a 1-year return of -37.22%.

Peers: The peers of Decipher Labs are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Span Divergent, Unjha Formul., Checkpoint Trend, Vivanza Biosci., and Cian Healthcare.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Dr Reddy's Labs, while Average management risk is found at Decipher Labs and Unjha Formul. Below Average management risk is noted for Checkpoint Trend, Vivanza Biosci., and Cian Healthcare. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is seen at Divi's Lab., Torrent Pharma, Decipher Labs, Unjha Formul., Checkpoint Trend, Vivanza Biosci., and Cian Healthcare. Excellent capital structure is present at Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, while Below Average capital structure is noted for Decipher Labs, and Average capital structure is observed at Unjha Formul. Good capital structure is seen at Torrent Pharma.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.96%, while Cian Healthcare has the lowest at -82.59%. Decipher Labs' 1-year return is -37.22%, which is significantly lower than the highest return and higher than the lowest. Additionally, the six-month return is negative for Decipher Labs, Span Divergent, Unjha Formul., and Vivanza Biosci.

Read More

Is Decipher Labs overvalued or undervalued?

09-Jun-2025

As of June 2, 2025, Decipher Labs is considered overvalued with a risky valuation grade, reflected by a negative PE ratio of -2.22, an EV to EBITDA of -1.20, and a year-to-date stock return of -24.62%, significantly underperforming its peers and the Sensex.

As of 2 June 2025, Decipher Labs has moved from an attractive to a risky valuation grade. The company is currently considered overvalued based on its financial metrics, with a PE ratio of -2.22, an EV to EBITDA of -1.20, and a ROCE of -38.00%. These figures indicate significant financial distress and lack of profitability, which is further underscored by a negative PEG ratio of 0.00.<BR><BR>In comparison to its peers, Decipher Labs stands out negatively; for instance, Sun Pharma has a PE ratio of 35.25 and an EV to EBITDA of 24.91, while Cipla shows a PE ratio of 22.99 and an EV to EBITDA of 15.93. The stark contrast in these ratios highlights Decipher Labs' struggles within the pharmaceuticals and biotechnology sector. Additionally, the company's stock has underperformed significantly against the Sensex, with a year-to-date return of -24.62% compared to the Sensex's 5.66%, reinforcing the notion that Decipher Labs is overvalued at its current price of 11.27.

Read More

What is the technical trend for Decipher Labs?

09-Jun-2025

As of June 4, 2025, Decipher Labs is in a bearish trend with moderate strength, driven by bearish daily moving averages and Bollinger Bands, despite some mildly bullish MACD signals.

As of 4 June 2025, the technical trend for Decipher Labs has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. Key indicators driving this include the daily moving averages, which are bearish, and the weekly and monthly Bollinger Bands also indicating a bearish trend. Although the MACD shows mildly bullish signals on both weekly and monthly time frames, the overall sentiment is dampened by the bearish moving averages and the Dow Theory, which is mildly bearish on both weekly and monthly scales. The stock's performance has significantly lagged behind the Sensex over various time frames, further supporting the bearish outlook.

Read More

Who are in the management team of Decipher Labs?

16-Jul-2025

As of March 2022, the management team of Decipher Labs includes Sushant Mohan Lal (Executive Director), G Venkateswara Rao (Independent Director), and Megha Agarwal (Company Secretary and Compliance Officer).

As of March 2022, the management team of Decipher Labs includes Sushant Mohan Lal, who serves as the Executive Director, G Venkateswara Rao, who is an Independent Director, and Megha Agarwal, who holds the position of Company Secretary and Compliance Officer.

Read More

What does Decipher Labs do?

17-Jul-2025

Decipher Labs Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of 35 Cr and a net loss of 41 Cr for the quarter ending March 2025. The company has a market cap of INR 12 Cr and is based in Hyderabad, India.

Overview:<BR>Decipher Labs Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>Decipher Labs Ltd was incorporated as a Private Limited Company in September 1986 and transitioned to a Public Limited Company in June 1992. The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 35 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -41 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 12 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.11 <BR>Return on Equity: -22.22% <BR>Price to Book: 0.52<BR><BR>Contact Details:<BR>Address: 4th Flr Plot-94 Sagar Society, Banjara Hills Road No 2 Hyderabad Telangana : 500034 <BR>Email: info@combatdrugs.in <BR>Website: http://www.combatdrugs.in

Read More

How big is Decipher Labs?

24-Jul-2025

As of 24th July, Decipher Labs Ltd has a market capitalization of 11.00 Cr and reported net sales of 22.61 Cr with a net loss of 5.08 Cr over the latest four quarters. Shareholder's funds were 21.86 Cr, and total assets were 33.08 Cr as of March 2024.

As of 24th July, Decipher Labs Ltd has a market capitalization of 11.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Decipher Labs reported net sales of 22.61 Cr. However, the company experienced a net loss of 5.08 Cr during the same period.<BR><BR>The latest annual period for the balance sheet is March 2024, where the shareholder's funds amounted to 21.86 Cr, and total assets were reported at 33.08 Cr.

Read More

Are Decipher Labs latest results good or bad?

15-Aug-2025

Decipher Labs' latest results are disappointing, with a Profit Before Tax of Rs -3.43 crore and a 64.39% decline in net sales to Rs 6.42 crore, indicating significant financial challenges and concerns about liquidity.

Decipher Labs' latest financial results are quite disappointing. For the quarter ending June 2025, the company reported a Profit Before Tax (PBT) of Rs -3.43 crore, which represents a staggering year-on-year decline of 385.83%. This indicates significant challenges in achieving profitability.<BR><BR>Moreover, net sales for the first half of the year fell to Rs 6.42 crore, down 64.39% compared to the previous year, highlighting severe revenue struggles. The Profit After Tax (PAT) also reflects this negative trend, with a reported figure of Rs -7.54 crore, again showing a decline of 64.39%.<BR><BR>Additionally, the company's cash and cash equivalents have decreased to Rs 2.81 crore, marking the lowest level in the last three half-yearly periods, which raises concerns about its short-term liquidity. While there has been a slight improvement in the overall financial score, the outlook for Decipher Labs remains challenging given these substantial declines in key financial metrics.

Read More

When is the next results date for Decipher Labs?

11-Nov-2025

Decipher Labs will announce its results on 13 November 2025.

Decipher Labs is scheduled to declare its results on 13 November 2025.

Read More

How has been the historical performance of Decipher Labs?

14-Nov-2025

Decipher Labs has experienced a significant decline in net sales and profitability from March 2022 to March 2025, with net sales dropping from 65.32 Cr to 22.61 Cr and operating profit turning negative, resulting in a loss of 5.08 Cr after tax. Total assets and liabilities also decreased during this period, alongside a negative cash flow from operating activities.

Answer:<BR>The historical performance of Decipher Labs shows a significant decline in net sales and profitability over the years, particularly from March 2022 to March 2025.<BR><BR>Breakdown:<BR>Decipher Labs experienced a decrease in net sales from 65.32 Cr in March 2022 to 22.61 Cr in March 2025. This downward trend is reflected in total operating income, which also fell from 65.32 Cr in March 2022 to 22.61 Cr in March 2025. The company's total expenditure, excluding depreciation, peaked at 59.29 Cr in March 2022 but decreased to 29.84 Cr by March 2025. Operating profit (PBDIT) turned negative, going from a profit of 6.03 Cr in March 2022 to a loss of 7.23 Cr in March 2025. Consequently, profit after tax also declined sharply, from 11.38 Cr in March 2022 to a loss of 5.08 Cr in March 2025. The company's total assets decreased from 41.95 Cr in March 2022 to 23.89 Cr in March 2025, while total liabilities also fell from 41.95 Cr to 23.89 Cr in the same period. Cash flow from operating activities showed a negative trend, with a cash outflow of 9.00 Cr in March 2025, compared to a positive inflow of 8.00 Cr in March 2022. Overall, Decipher Labs has faced significant challenges in maintaining sales and profitability over the years.

Read More

Should I buy, sell or hold Decipher Labs?

16-Nov-2025

Which are the latest news on Decipher Labs?

04-Dec-2025

Why is Decipher Labs falling/rising?

04-Dec-2025

As of 04-Dec, Decipher Labs Ltd's stock price is rising to 9.67, reflecting a short-term upward trend after previous declines, but it remains below its moving averages, indicating potential long-term challenges. Despite a significant increase in investor participation, the stock has faced substantial declines over the year.

As of 04-Dec, Decipher Labs Ltd's stock price is rising, currently at 9.67, with a change of 0.18 (1.9%) upward. This increase follows a trend reversal, as the stock has gained after two consecutive days of decline. Additionally, the stock has outperformed its sector by 1.61%, indicating a relative strength compared to its peers. <BR><BR>Despite the positive movement today, it is important to note that Decipher Labs is trading lower than its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This suggests that while there is a short-term rise, the longer-term trend may still be downward. <BR><BR>Moreover, there has been a notable increase in investor participation, with delivery volume rising by 75.7% compared to the 5-day average, which may contribute to the stock's upward movement. However, the stock has experienced significant declines over longer periods, such as a year-to-date drop of 35.32% and a one-year decline of 39.34%, indicating ongoing challenges despite today's positive performance.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Weak Long Term Fundamental Strength with a -230.89% CAGR growth in Operating Profits over the last 5 years

  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -2.96
  • The company has been able to generate a Return on Capital Employed (avg) of 5.19% signifying low profitability per unit of total capital (equity and debt)
2

The company has declared Negative results for the last 5 consecutive quarters

3

Risky - Negative EBITDA

4

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters
Mojo Parameters
Loading Valuation Snapshot...
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

INR 10 Cr (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

34

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.02

stock-summary
Return on Equity

-42.37%

stock-summary
Price to Book

0.50

Revenue and Profits:
Net Sales:
4 Cr
(Quarterly Results - Sep 2025)
Net Profit:
0 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-8.95%
0%
-8.95%
6 Months
-10.21%
0%
-10.21%
1 Year
-39.34%
0%
-39.34%
2 Years
-42.65%
0%
-42.65%
3 Years
-66.6%
0%
-66.6%
4 Years
-85.33%
0%
-85.33%
5 Years
-64.77%
0%
-64.77%

Decipher Labs for the last several years.

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions
News

Why is Decipher Labs falling/rising?

Recent Price Movement and Market Context

Decipher Labs has experienced a subtle but consistent decline in the last three trading sessions, cumulatively losing 4.83% in value. This short-term weakness contrasts with its weekly and monthly returns, which remain positive at +2.40% and +4.07% respectively, outperforming the Sensex benchmarks of +0.79% and +0.95% over the same periods. However, the longer-term performance paints a more challenging picture. Year-to-date, the stock has declined by 31.51%, significantly underperforming the Sensex’s 9.08% gain. Over one, three, and five-year horizons, Decipher Labs has posted steep losses of 32.81%, 64.07%, and 58.79% respectively, while the Sensex has delivered robust positive returns, underscoring the stock’s persistent struggles re...

Read More
Announcements stock-summary

Board Meeting Outcome for Outcome Of The Board Meeting Held On 13.11.2025

13-Nov-2025 | Source : BSE

Outcome of the Board Meeting held on 13.11.2025

Unaudited Financial Results For The Quarter And Half Year Ended 30.09.2025

13-Nov-2025 | Source : BSE

Unaudited financial results for the quarter and half year ended 30.09.2025

Announcement under Regulation 30 (LODR)-Change in Management

13-Nov-2025 | Source : BSE

Appointment of Mr. Dalavath Amar Singh as Additional Director ( Executive Category) of the Company

Corporate Actions stock-summary
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

No Dividend history available

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available

stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-19.55%
EBIT Growth (5y)
-230.89%
EBIT to Interest (avg)
-2.96
Debt to EBITDA (avg)
1.24
Net Debt to Equity (avg)
-0.02
Sales to Capital Employed (avg)
1.64
Tax Ratio
17.53%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
-16.88%
ROE (avg)
14.54%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
34
Price to Book Value
0.51
EV to EBIT
-0.86
EV to EBITDA
-0.90
EV to Capital Employed
0.50
EV to Sales
0.57
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-58.12%
ROE (Latest)
-42.37%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Non Institution

Pledged Promoter Holdings

None

Mutual Funds

Held by 0 Schemes

FIIs

Held by 0 FIIs

Promoter with highest holding

Ajjarapu Janakiram (16.43%)

Highest Public shareholder

Seshu Srinivas Akula (3.8%)

Individual Investors Holdings

78.73%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is -26.58% vs -21.63% in Sep 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 101.50% vs 31.44% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "4.31",
          "val2": "5.87",
          "chgp": "-26.58%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.12",
          "val2": "-1.33",
          "chgp": "109.02%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "0.02",
          "val2": "-1.33",
          "chgp": "101.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "2.78%",
          "val2": "-22.66%",
          "chgp": "25.44%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Consolidated) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2025 is -45.60% vs -21.71% in Sep 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": " Growth in half year ended Sep 2025 is -797.37% vs 86.85% in Sep 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "7.24",
          "val2": "13.31",
          "chgp": "-45.60%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.19",
          "val2": "-0.02",
          "chgp": "-15,850.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.41",
          "val2": "-0.38",
          "chgp": "-797.37%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-44.06%",
          "val2": "-0.15%",
          "chgp": "-43.91%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2024 is -24.44% vs -29.36% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2024 is 66.32% vs -343.08% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "19.11",
          "val2": "25.29",
          "chgp": "-24.44%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.66",
          "val2": "-2.17",
          "chgp": "69.59%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.01",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.97",
          "val2": "-2.88",
          "chgp": "66.32%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-3.45%",
          "val2": "-8.58%",
          "chgp": "5.13%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is -36.98% vs -21.26% in Mar 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is -202.38% vs 37.31% in Mar 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "22.61",
          "val2": "35.88",
          "chgp": "-36.98%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-7.23",
          "val2": "-0.96",
          "chgp": "-653.13%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.22",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-5.08",
          "val2": "-1.68",
          "chgp": "-202.38%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-31.98%",
          "val2": "-2.68%",
          "chgp": "-29.30%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Sep'25 - YoYstock-summary
Sep'25
Sep'24
Change(%)
Net Sales
4.31
5.87
-26.58%
Operating Profit (PBDIT) excl Other Income
0.12
-1.33
109.02%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
0.02
-1.33
101.50%
Operating Profit Margin (Excl OI)
2.78%
-22.66%
25.44%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in quarter ended Sep 2025 is -26.58% vs -21.63% in Sep 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Sep 2025 is 101.50% vs 31.44% in Sep 2024

Half Yearly Results Snapshot (Consolidated) - Sep'25stock-summary
Sep'25
Sep'24
Change(%)
Net Sales
7.24
13.31
-45.60%
Operating Profit (PBDIT) excl Other Income
-3.19
-0.02
-15,850.00%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-3.41
-0.38
-797.37%
Operating Profit Margin (Excl OI)
-44.06%
-0.15%
-43.91%
Values in Rs Cr.
Direction Arrows
Net Sales

Growth in half year ended Sep 2025 is -45.60% vs -21.71% in Sep 2024

Direction Arrows
Consolidated Net Profit

Growth in half year ended Sep 2025 is -797.37% vs 86.85% in Sep 2024

Nine Monthly Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
19.11
25.29
-24.44%
Operating Profit (PBDIT) excl Other Income
-0.66
-2.17
69.59%
Interest
0.00
0.01
-100.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-0.97
-2.88
66.32%
Operating Profit Margin (Excl OI)
-3.45%
-8.58%
5.13%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in nine months ended Dec 2024 is -24.44% vs -29.36% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in nine months ended Dec 2024 is 66.32% vs -343.08% in Dec 2023

Annual Results Snapshot (Consolidated) - Mar'25stock-summary
Mar'25
Mar'24
Change(%)
Net Sales
22.61
35.88
-36.98%
Operating Profit (PBDIT) excl Other Income
-7.23
-0.96
-653.13%
Interest
0.00
0.22
-100.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-5.08
-1.68
-202.38%
Operating Profit Margin (Excl OI)
-31.98%
-2.68%
-29.30%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2025 is -36.98% vs -21.26% in Mar 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2025 is -202.38% vs 37.31% in Mar 2024

stock-summaryCompany CV
About Decipher Labs Ltd stock-summary
stock-summary
Decipher Labs Ltd
Micro Cap
Pharmaceuticals & Biotechnology
Decipher Labs Ltd. (formerly known as Combat Drugs Ltd) was incorporated as a Private Limited Company in September, 1986 and was converted into a Public Limited Company in Jun.'92. The company was promoted by Suchit Mohan Lal and Ajay Karan.
Company Coordinates stock-summary
Company Details
4th Flr Plot-94 Sagar Society, Banjara Hills Road No 2 Hyderabad Telangana : 500034
stock-summary
Tel:
stock-summary
info@combatdrugs.in
Registrar Details
Venture Capital & Corporate Investments Ltd , 12-10-167,, MIG- 167,, Bharat Nagar Colony, Hyderabad